CV6 Therapeutics

R&D Team

Kylie A. McLaughlin,

Associate-Principal Scientist

Dr. Kylie A. McLaughlin PhD has 17 years of experience in the field of biomedical science and oncology. Kylie was the first scientist to join the CV6 Therapeutics R&D Team in 2015. Kylie’s research expertise spans drug development, cancer drug resistance mechanisms, DNA damage, cell death, and nucleotide metabolism.

At CV6, Kylie has been actively involved in small molecule inhibitor screening and the pre-clinical evaluation of candidate compounds in the CV6 pipeline. Importantly, playing a key role in the pre-clinical development of CV6-168. Currently, Kylie’s research focus is on the development and validation of pharmacodynamic biomarkers, translating mechanism-of-action insights. As Quality Team Principal, Kylie jointly led the design and implementation of the laboratory’s Quality Management System (QMS) and integration of the Laboratory Information Management System (LIMS).

Kylie holds a first-class BSc (Hons) in Biomedical Science from Queen’s University Belfast and received the IBMS President’s Prize for outstanding achievement. Kylie completed her PhD in 2015 within Prof. Patrick G. Johnston’s laboratory under the supervision of Professors Dan Longley and Kevin Prise, investigating chemotherapy and radiation resistance in lung cancer. Kylie was admitted as a Fellow of the Institute of Biomedical Science in 2017.

CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel combination therapies